{
    "nctId": "NCT00290758",
    "briefTitle": "Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer",
    "officialTitle": "Phase IIB Trial of G-2535 (Unconjugated Isoflavones-100) in Women at High Risk for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 126,
    "primaryOutcomeMeasure": "Change in Breast Epithelial Cell Proliferation as Measured by Ki-67 Labeling",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* No known soy intolerance\n* At increased risk of developing breast cancer in \\>= 1 previously unaffected breast, as defined by any of the following:\n\n  * Estimated 5-year risk of developing breast cancer using the Gail model, as defined by 1 of the following:\n\n    * Gail score \\>= 1.66%\n    * Gail score \\>= 0.1% for women age 20-29 years\n    * Gail score \\>= 1.0% for women age 30-39 years\n  * Estimated 5-year risk of developing breast cancer using the Claus model:\n\n    * Claus score \\>= 1.66%\n    * Claus score \\>= 0.1% for women age 20-29 years\n    * Claus score \\>= 1.0% for women age 30-39 years\n  * Prior diagnosis of unilateral in situ or invasive breast cancer OR history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity\n  * History of lobular carcinoma in situ\n* No evidence of breast cancer, as determined by a negative mammogram within the past 6 months and a history and physical\n* No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago\n* Pre- or postmenopausal\n* ECOG performance status 0-1\n* Hemoglobin \\> 10.0 g/dL\n* Platelet count \\> 100,000/mm\\^3\n* Absolute neutrophil count \\> 1,000/mm\\^3\n* Creatinine \\< 2.0 mg/dL\n* SGPT \\< 82 U/L\n* SGOT \\< 68 U/L\n* Bilirubin \\< 3 mg/dL\\* \\[Note: \\* Patients with a higher level of bilirubin due to a familial metabolism may be eligible at the discretion of the investigator\\]\n* Life expectancy \\> 2 years\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception\n* Must be willing to keep a dietary diary\n* No venous thrombosis within the past year\n* No unrecognized or poorly controlled thyroid disease\n* No other cancer within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical cancer\n* No other medical condition that, in the opinion of the investigator, would jeopardize either the patient or the integrity of the data obtained\n* None of the following for \\>= 2 weeks before the first random fine needle aspiration and during study participation:\n\n  * Oral contraceptives\n  * Soy supplements\n  * High soy-containing foods\n  * Fish oil supplements\n  * Multivitamins\n  * Vitamins C and E\n  * Daily aspirin or nonsteroidal\n  * Anti-inflammatory drugs\n* No other concurrent investigational agents\n* No concurrent warfarin or other blood thinners\n* Female patient\n\nExclusion Criteria:\n\nWomen previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously\n\n* Currently pregnant, or planning to become pregnant during the study period\n* History of venous thrombosis within past year\n* Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained\n* History of other cancer within the past five years, excluding non-melanomatous skin cancer, and non-invasive cervical cancer\n* Known soy intolerance\n* Unrecognized or uncontrolled thyroid disease, subjects may be on synthroid, but thyroid function must be in normal range or the patient's physician must document that the patient's thyroid is controlled.\n* Currently receiving any other investigational agents\n* Currently on coumadin, or other blood thinners\n* History of breast augmentation implants.\n* Rusults from patients who have \\<4000 epithelial cells in either the first or the second random Fine-needle aspiration (rFNA) will not be included in the study.",
    "sex": "FEMALE",
    "minimumAge": "25 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}